← Back to Search

Antisense Oligonucleotide

STP705 for Keloid

Phase 2
Waitlist Available
Led By David Goldberg, MD
Research Sponsored by Sirnaomics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights

Summary

This trial is testing whether a new medication can reduce the chances of a keloid (a raised scar) coming back after surgery to remove it. The trial is comparing different doses of the medication to see which is most effective with the least side effects.

Eligible Conditions
  • Keloid

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Rate of Recurrence
Secondary outcome measures
Change in DLQI score
Change in mVSS score
Change of Keloid scar appearance
+2 more

Trial Design

6Treatment groups
Experimental Treatment
Active Control
Placebo Group
Group I: Cohort 4: STP705 40 μg doseExperimental Treatment1 Intervention
STP705 at the assigned dose will be injected intradermal into the excised keloid site
Group II: Cohort 3: STP705 30 μg doseExperimental Treatment1 Intervention
STP705 at the assigned dose will be injected intradermal into the excised keloid site
Group III: Cohort 2: STP705 20 μg doseExperimental Treatment1 Intervention
STP705 at the assigned dose will be injected intradermal into the excised keloid site
Group IV: Cohort 1: STP705 10 μg doseExperimental Treatment1 Intervention
STP705 at the assigned dose will be injected intradermal into the excised keloid site
Group V: Cohort 6: SOC aloneActive Control1 Intervention
SOC (no injection)
Group VI: Cohort 5: Placebo controlPlacebo Group1 Intervention
Placebo (saline) will be injected intradermal into the excised keloid site
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
STP705
2022
Completed Phase 2
~180

Find a Location

Who is running the clinical trial?

SirnaomicsLead Sponsor
11 Previous Clinical Trials
308 Total Patients Enrolled
David Goldberg, MDPrincipal InvestigatorSchweiger Dermatology Group
3 Previous Clinical Trials
118 Total Patients Enrolled
Brenda LaTowsky, MDPrincipal InvestigatorInvestigate MD
1 Previous Clinical Trials
44 Total Patients Enrolled
~7 spots leftby Jul 2025